EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata

Longyan Yao, Jiumei He, Na Lan, Yongmei Lv iD

Journal of Cosmetic Dermatology · 2025-07 · 24 (7)

DOI: 10.1111/jocd.70234 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 02.07.2025. Verfasst von Longyan Yao und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors, Piperidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Fund of Anhui Institute of Translational Medicine, Clinical Research Cultivation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA) is an autoimmune disorder mediated by T cells, resulting in hair loss on the scalp, eyebrows, and body. Conventional treatments for AA often exhibit high recurrence rates and various side effects. Recently, Janus kinase (JAK) inhibitors have emerged as promising therapeutic options for managing AA and several other autoimmune disorders. Case Presentation We present the case of a 26‐year‐old patient who initially responded well to Tofacitinib but subsequently experienced relapses during the treatment period. Corticosteroid therapy was effective in managing these relapses, leading to a transition to Ritlecitinib when Tofacitinib monotherapy became unsustainable.

Discussion

In cases where monotherapy proves ineffective, alternative strategies such as combination therapy, dose optimization, or switching to different therapeutic agents should be considered. While the JAK–STAT signaling pathway plays a pivotal role in the pathogenesis of AA, it is likely that additional mechanisms also contribute to its development.

Conclusion

We present a case report documenting secondary failure of tofacitinib in the treatment of AA. This case highlights potential insights into the pathogenesis of AA and may inform the development of future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolesAdultHumansRecurrenceTreatment Failure

Stichwörter der Autor:innen

JAK inhibitoralopecia areatatherapytofacitinib

Substanzen

Janus Kinase InhibitorsPiperidinesProtein Kinase InhibitorsPyrimidinesPyrrolestofacitinib

Autor:innen und Institutionen

  • The Second Affiliated Hospital of Anhui Medical University, Hefei, China.

ORCID-Profile: Yongmei Lv

Förderung

  • Research Fund of Anhui Institute of Translational Medicine
  • Clinical Research Cultivation Program

Zitieren

APA

Yao, L., He, J., Lan, N., & Lv, Y. (2025). Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata. Journal of Cosmetic Dermatology, 24(7). https://doi.org/10.1111/jocd.70234

Vancouver

Yao L, He J, Lan N, Lv Y. Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata. Journal of Cosmetic Dermatology. 2025;24(7). doi:10.1111/jocd.70234

BibTeX
@article{Yao2025,
  author = {Yao, Longyan and He, Jiumei and Lan, Na and Lv, Yongmei},
  title = {Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  volume = {24},
  number = {7},
  doi = {10.1111/jocd.70234}
}
Kostenlos starten →